Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoKnife for Stage 3 Pancreatic Cancer
NCT03899636Phase 3Active, not recruiting
- Sponsor
- AngioDynamics
- Start
- Feb 2021
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by AngioDynamics. Primary endpoint: Overall Survival at 24 months. Started Feb 2021; status: active, not recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03899636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899636.